Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.62 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.62 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336164 | 0.98 | CHRM2 (0.65) | BLMMCOLN3LMNACHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL11584066 | 0.96 | CHRM2 (0.62) | BLMMCOLN3LMNACHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL2197726 | 0.96 | CHRM2 (0.62) | BLMMCOLN3LMNACHRM2CHRM4 | |
| Ammonia Solution, Strong SCHEMBL30785800 | 0.96 | CHRM2 (0.62) | BLMMCOLN3LMNACHRM2CHRM4 | |
| Bromide SCHEMBL10920212 | 0.84 | BLM (0.66) | BLMMCOLN3LMNACHRM2CHRM4 | |
| SCHEMBL9568926 | 0.82 | CHRM2 (0.65) | BLMMCOLN3LMNACHRM2CHRM4 | |
| SCHEMBL5203140 | 0.82 | CHRM2 (0.65) | BLMMCOLN3LMNACHRM2CHRM4 | |
| Arecoline SCHEMBL527735 | 0.79 | BLM (1.00) | BLMMCOLN3LMNACHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL1897878 | 0.78 | CHRM2 (0.61) | BLMMCOLN3LMNACHRM2CHRM4 | |
| Arecoline SCHEMBL44065 | 0.77 | CHRM2 (1.00) | BLMMCOLN3LMNACHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257848-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | Novartis AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| EP-2773635-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR ACTIVITY | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9440957-B2 | Compounds and compositions for modulating EGFR Activity | NOVARTIS AG (CH) | 2016-09-13 | — | — | US | disclosed |
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-07-16 | — | — | US | disclosed |
| EP-0537993-A1 | Nicotinic activity of a series of arecolones and isoarecolones | ELI LILLY AND COMPANY (US) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | EGFR, ERBB2, ERBB3 | CHRM2 3853/4885CHRM3 3339/4885BLM 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.